514NewsMetalloinvest Opens Its Green Metallurgy Enterprises to Tourists
MOSCOW, RUSSIA – Media OutReach – 11 September 2023 – Metalloinvest, a pioneer of green metallurgy in Russia, has opened its enterprises...
- 463Wire Stories
Dorsey’s Shanghai Office Moves to CITIC Square
SHANGHAI–(BUSINESS WIRE)–The Shanghai office of international law firm Dorsey & Whitney has moved to a new address: CITIC Square, Suite 3707-3708, 1168...
- 448Wire Stories
Best’s Market Segment Report: Operating Performance, Retro Cost Drive Asian Reinsurer Strategies
HONG KONG–(BUSINESS WIRE)–#insurance–Despite a sharp increase in catastrophe losses outside their home markets and a challenging investment environment, major Asia-Pacific reinsurance companies...
- 428Wire Stories
SolarWinds to Participate in Gartner IT Symposium/Xpo 2023 Worldwide Events
SolarWinds will showcase its product portfolio and speak on how integrated observability and service management solutions help ensure operational resiliency AUSTIN, Texas–(BUSINESS...
- 410News
pCloud Celebrates a Decade of Innovation and Security in Online Storage: A Decade of Data Management Excellence
ZUG, SWITZERLAND – Media OutReach – 11 September 2023 – pCloud, the leading platform in online storage and data management, proudly commemorates...
- 488Wire Stories
Celltrion Celebrates a Decade of Biosimilar Innovation in Europe
Today marks 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all indications of...
- 736Wire Stories
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
Encouraging objective response rate of 52.4% was seen with ifinatamab deruxtecan in heavily pretreated patients IDeate-01 phase 2 trial currently enrolling patients...
- 539Wire Stories
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial
An objective response rate of 29.8% was observed with patritumab deruxtecan in heavily pretreated patients BLA submission in U.S. planned for the...
- 681Wire Stories
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab with or without chemotherapy demonstrated objective response rates of 77% and 50% and disease...
- 446News
Hong Kong Survey Reveals Over Half of Middle-Aged and Elderly Unvaccinated Due to Low Pneumococcal Vaccination Awareness
Medical professionals and social organizations call for increased awareness of pneumococcal threat and strengthened preventative measures among high-risk individuals HONG KONG SAR...
